After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment
On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) announced plans to voluntarily withdraw the U.S. accelerated approval for ...
STAT7h
RFK Jr. alarms leaders in health, even many in GOP
“The RFK announcement has kind of scrambled some of the traditional thinking [about] a lot of the people that have been ...
Business Facilities4h
Biotech/Pharmaceutical Industry: Good Medicine, Great Locations
Here are some regions that are attracting biotech and pharma companies.
BioSpace12h
It’s Earnings Season. Here’s What to Watch for Following J&J Beat
This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street’s expectations.
BioNTech shares slip as FDA places partial clinical hold on lung cancer study
BioNTech (NASDAQ:BNTX) shares fell Friday after the company said it had been informed by partner OncoC4 that FDA placed partial clinical hold on Phase 3 study of BNT316/ONC-392 (gotistobart) in ...
STAT14h
Potential competition for RSV prophylactic Beyfortus
New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...
The Lancet5h
Driving down the cost of biologics: lessons from a nationalised health-care system
Few treatments have revolutionised care for people with chronic inflammatory disorders more than biologic and small molecule ...